In this fifth phase of development, the contents of the Spanish Asthma Management Guidelines (GEMA), which include versions 5.0 and 5.1, have undergone a thorough review. The aim here is to set the main changes in context. These could be summarized as follows: DIAGNOSIS: new FE NO cut-off and severity classification based on treatment needed to maintain control; INTERMITTENT ASTHMA: a more restrictive concept and treatment extended to include a glucocorticoid/adrenergic combination as needed; MILD ASTHMA: glucocorticoid/adrenergic therapy as needed as an alternative in case of low therapeutic adherence to conventional fixed-dose steroids; SEVERE ASTHMA: readjustment of phenotypes, incorporation of triple therapy in a single inhaler, and criteria for selection of a biologic in severe uncontrolled asthma; OTHERS: specific scoring in childhood asthma, incorporation of certain organizational aspects (care circuits, asthma units, telemedicine), new sections on COVID-19 and nasal polyposis.

Original languageEnglish
Pages (from-to)T150-T158
JournalArchivos de bronconeumologia
Issue number2
Publication statusPublished - Feb 2022


  • Adrenergic Agents/therapeutic use
  • Asthma/drug therapy
  • COVID-19
  • Glucocorticoids/therapeutic use
  • Humans


Dive into the research topics of '[Translated article] Spanish Asthma Management Guidelines (GEMA) v.5.1. Highlights and Controversies'. Together they form a unique fingerprint.

Cite this